Central Pharmaceutical No3 Past Earnings Performance
Past criteria checks 6/6
Central Pharmaceutical No3 has been growing earnings at an average annual rate of 8.4%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 1% per year. Central Pharmaceutical No3's return on equity is 25.1%, and it has net margins of 31.3%.
Key information
8.4%
Earnings growth rate
6.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | 1.0% |
| Return on equity | 25.1% |
| Net Margin | 31.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Central Pharmaceutical No3 makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 393,677 | 123,060 | 133,919 | 0 |
| 31 Dec 23 | 409,722 | 125,254 | 144,632 | 0 |
| 30 Sep 23 | 437,247 | 115,462 | 169,115 | 0 |
| 30 Jun 23 | 454,355 | 112,885 | 182,654 | 0 |
| 31 Mar 23 | 478,070 | 110,902 | 203,010 | 0 |
| 31 Dec 22 | 485,074 | 108,824 | 208,717 | 0 |
| 30 Sep 22 | 466,732 | 100,148 | 208,813 | 0 |
| 30 Jun 22 | 439,432 | 97,217 | 197,198 | 0 |
| 31 Mar 22 | 410,106 | 98,580 | 164,388 | 0 |
| 31 Dec 21 | 381,077 | 94,305 | 151,491 | 0 |
| 30 Sep 21 | 377,540 | 100,467 | 145,037 | 0 |
| 30 Jun 21 | 384,213 | 106,614 | 142,369 | 0 |
| 31 Mar 21 | 381,982 | 109,143 | 139,242 | 0 |
| 31 Dec 20 | 395,721 | 114,061 | 140,383 | 0 |
| 30 Sep 20 | 390,308 | 79,192 | 170,341 | 0 |
| 30 Jun 20 | 414,641 | 84,092 | 176,959 | 0 |
| 31 Mar 20 | 417,252 | 84,281 | 161,353 | 0 |
| 31 Dec 19 | 411,433 | 82,804 | 159,912 | 0 |
| 30 Sep 19 | 422,776 | 78,546 | 171,428 | 0 |
| 30 Jun 19 | 433,396 | 78,929 | 172,016 | 0 |
| 31 Mar 19 | 451,125 | 82,658 | 185,495 | 0 |
| 31 Dec 18 | 471,503 | 80,071 | 194,904 | 0 |
| 30 Sep 18 | 439,461 | 92,382 | 156,619 | 0 |
| 31 Dec 17 | 328,141 | 38,335 | 138,589 | 0 |
| 30 Sep 17 | 321,383 | 30,929 | 138,891 | 0 |
| 31 Dec 16 | 237,634 | 22,503 | 89,165 | 0 |
| 30 Sep 16 | 224,750 | 20,748 | 83,189 | 0 |
| 31 Dec 15 | 212,098 | 16,220 | 76,032 | 0 |
| 30 Sep 15 | 198,874 | 8,695 | 69,041 | 0 |
| 30 Jun 15 | 191,613 | 7,996 | 62,061 | 0 |
| 31 Mar 15 | 187,955 | 9,843 | 59,081 | 0 |
| 31 Dec 14 | 184,296 | 11,690 | 56,102 | 0 |
| 01 Jan 14 | 151,880 | 7,943 | 45,467 | 0 |
Quality Earnings: DP3 has high quality earnings.
Growing Profit Margin: DP3's current net profit margins (31.3%) are higher than last year (23.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DP3's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: DP3's earnings growth over the past year (11%) exceeds its 5-year average (8.4% per year).
Earnings vs Industry: DP3 earnings growth over the past year (11%) exceeded the Pharmaceuticals industry -3.3%.
Return on Equity
High ROE: DP3's Return on Equity (25.1%) is considered high.